Vytorin
Vytorin Side Effects May Result In Clogged Arteries Lawsuits
Vytorin Side Effects Injury Lawsuits. On January 14, 2008, the results of a long-awaited study on the effectiveness of Vytorin to reduce artery clogging plaque in patients with high cholesterol were released. The ENHANCE study found that Vytorin, a combination of cholesterol lowering Zetia and the statin Zocor, worked no … [Read more...] about Vytorin Side Effects May Result In Clogged Arteries Lawsuits
Vytorin Makers Spent Millions on Medical Education
Vytorin Makers Spent Millions on Medical Education Merck & Co. and Schering-Plough, the makers of Vytorin, spent millions over the past four years to educate doctors about the latest treatments for heart disease, according to The Wall Street Journal. Critics of the pharmaceutical industry assert that marketing, not medical … [Read more...] about Vytorin Makers Spent Millions on Medical Education
Vytorin Makers $41.5M Settlement
Vytorin Makers Class Action Settlement. Vytorin is a combination of Zetia and the statin Zocor. It has been under the microscope since the ENHANCE study was released in January 2008. ENHANCE found that the drug was no better than a cheaper, generic statin in preventing clogged arteries, and raised serious questions about … [Read more...] about Vytorin Makers $41.5M Settlement
Vytorin Named in Lawsuit
Vytorin Named in Another Lawsuit. Disputed (PEBTF) has filed suit against Merck & Co. and Schering-Plough, alleging that the companies charged too much for both Vytorin, and Zetia, another cholesterol drug, which is also a component of Vytorin. Vytorin, a combination of the statin Zocor (simvastatin) and Zetia, has been under … [Read more...] about Vytorin Named in Lawsuit
Vytorin Probe Seeks Information
Vytorin Probe Seeks Information. Lawmakers investigating the cholesterol drug Vytorin have asked Merck and Schering-Plough for more information on the medication's clinical trials. According to Reuters, Rep. Henry Waxman (D-Calif), chairman of the House Energy and Commerce Committee, has written two companies on Thursday seeking … [Read more...] about Vytorin Probe Seeks Information
Vytorin, Zetia Disappoint Again
Vytorin, Zetia Disappoint Vytorin and Zetia, Merck & Co.'s anti-cholesterol medications, are coming under fire again. A new study has found that a much older - and cheaper - drug reduced artery plaque much better in eight months than ezetimibe, the active ingredient in both Vytorin and Zetia. According to USA Today, this … [Read more...] about Vytorin, Zetia Disappoint Again
Experts Divided on Cancer Risk of Vytorin
Vytorin Potential Cancer Risk. Vytorin was the subject of a heated debate at the annual meeting of the American Heart Association in New Orleans yesterday. At issue was the controversial drug's potential cancer risk. While some heart experts on a panel discussing the issue tried to ease concerns about Vytorin and cancer, … [Read more...] about Experts Divided on Cancer Risk of Vytorin
New Haven to Sue Merck and Schering-Plough
Merck and Schering-Plough Lawsuit. The city of New Haven, Connecticut, is reporting that over $400,000 in tax dollars were spent on Vytorin and Zetia for employees. Now, corporation counsel John Ward is seeking return of that money over ongoing claims that Vitorin “doesn’t work” he said in an interview with The New Haven … [Read more...] about New Haven to Sue Merck and Schering-Plough
Vytorin Confusion Leaves Patients Wondering
Vytorin Confusion Leaves Patients Wondering. Many patients - and probably some doctors - are scratching their heads over Vytorin. Though it has been on the market for four years, little is known about its safety and effectiveness. This year, two studies - ENHANCE and SEAS - have only added to the confusion over the … [Read more...] about Vytorin Confusion Leaves Patients Wondering
Vytorin Cancer Controversy Far from Over
Vytorin Cancer Controversy. News earlier this summer that Vytorin had been tied to a higher risk of cancer by a newly published study quickly faded from the headlines. Merck and Schering-Plough's reassurance that the cancer finding in the SEAS study was an anomaly apparently squashed much discussion of the issue - at least … [Read more...] about Vytorin Cancer Controversy Far from Over
Vytorin – Cancer Link Draws Congressional Scrutiny
Vytorin May Cause Risk Of Cancer. Cancer Link Draws Congressional Scrutiny, Lawmakers on a congressional committee want to see the results of a new study that indicated patients taking Vytorin might be at a higher risk of cancer. That study, known as SEAS, was given to the Food & Drug Administration (FDA), but has yet to be … [Read more...] about Vytorin – Cancer Link Draws Congressional Scrutiny
Vytorin Makers Defend Drug
Vytorin Makers Defend Drug. Vytorin makers Merck and Schering-Plough are preparing to send a letter to thousands of physicians in an attempt to address cancer concerns raised by a recently published study. While the companies acknowledge that Vytorin users enrolled in the SEAS study had higher rates of cancer than those … [Read more...] about Vytorin Makers Defend Drug
Another Vytorin Failure
Another Vytorin Failure. Yesterday's news that Vytorin failed to meet the primary endpoint in another important study has not done much to restore faith in the controversial cholesterol drug. First shown to be ineffective in preventing clogged arteries, it now seems Vytorin does little to help patients with aortic … [Read more...] about Another Vytorin Failure
Vytorin Falls Short in Study, Cancer Link Found
Vytorin Falls Short in Another Study. Vytorin, the controversial cholester found that patients taking Vytorin in the study were more likely to develop cancer. Vytorin, which was developed and marketed jointly by Merck and Schering-Plough, was approved for use by the Food & Drug Administration (FDA) in 2004. Since it came on the … [Read more...] about Vytorin Falls Short in Study, Cancer Link Found
Senator McCain Quit Vytorin After ENHANCE
Senator McCain Quit Vytorin. Many former Vytorin patients switched off the expensive drug after a study -called ENHANCE - released earlier this year showed it was no more effective than cheaper statins. Now it turns out that one of those patients was none other than Republican presidential nominee Senator John … [Read more...] about Senator McCain Quit Vytorin After ENHANCE
UnitedHealth Group Says it Will Still Cover Vytorin
UnitedHealth Group Still Cover Vytorin. Vytorin coverage will not change for people enrolled in health plans provided by UnitedHealth Group. The nation's largest health insurer said it will continue paying for Vytorin, even though a recently released study showed it worked no better than cheaper statin drugs. Many health insurers … [Read more...] about UnitedHealth Group Says it Will Still Cover Vytorin
Insurers Reassess Vytorin Coverage
Vytorin Provided No Added Benefits. Insurers are said to be reconsidering coverage for Vytorin, after a study showed the cholesterol-lowering drug provided no added benefits over cheaper statins. Already, one large insurer has changed its approach to Vytorin coverage, and it is thought others will follow. Vytorin, which … [Read more...] about Insurers Reassess Vytorin Coverage
Vytorin Emails Raise Questions About ENHANCE Delay
Vytorin Emails Raise Questions The Vytorin fallout continues, with one lawmaker demanding that Vytorin's makers explain why the results of a crucial study were delayed for more than a year. The request for more information on the delayed Vytorin study came just a day after a panel of prominent cardiologists recommended that Vytorin … [Read more...] about Vytorin Emails Raise Questions About ENHANCE Delay
Vytorin Prescriptions Still Lag
Vytorin Prescriptions Still Lag.Vytorin prescriptions have yet to recover from the dive they took in January, following the release of a study that showed the expensive cholesterol-lowering medication provides no more benefits than a cheaper statin. And Vytorin could take an even bigger hit later this month when that study, known as … [Read more...] about Vytorin Prescriptions Still Lag
Vytorin Probe Targets Message Board Posts
Vytorin Probe Message Board Posts. The Vytorin probe in Congress took another turn this week, with investigators seeking information on several posts left on internet message boards frequented by people working in the pharmaceutical industry. Vytorin, and its makers Merck and Schering-Plough, have been under … [Read more...] about Vytorin Probe Targets Message Board Posts
Vytorin Lawsuits Keep Coming
Merck and Schering-Plough Vytorin Lawsuits. Vytorin makers Merck and Schering-Plough are facing yet another lawsuit, this time from the plaintiffs in Nevada. The Nevada Vytorin consumer fraud lawsuit alleges that Merck and Schering-Plough deceived heart patients in that state by leading them to believe that Vytorin was more effective … [Read more...] about Vytorin Lawsuits Keep Coming
Vytorin in Connecticut Crosshairs
Connecticut's Merck and Schering-Plough Vytorin Investigation. Connecticut can now be added to the list of states investigating Vytorin. According to The Wall Street Journal, Connecticut Attorney General Richard Blumenthal announced that his office investigating Merck and Schering-Plough for claims the companies made about … [Read more...] about Vytorin in Connecticut Crosshairs
Vytorin Mess Attracts Attention of New York Attorney General
Vytorin Mess Attracts Attention. The Vytorin mess seems to be getting worse for Merck and Schering-Plough. Already facing a firestorm over its handling of the so-called ENHANCE study that found Vytorin worked no better than cheaper generic statins, the companies now face a subpoena from the New York State Attorney … [Read more...] about Vytorin Mess Attracts Attention of New York Attorney General
Early Communication Issued by FDA about Vytorin
FDA Reviews Vytorin. The Food & Drug Administration (FDA) weighed in on the Vytorin controversy today by issuing an Early Communication about its ongoing reviews of Vytorin, Zetia and Zocor. The FDA communication was prompted by preliminary results of the ENHANCE study that showed Vytorin was no better at preventing … [Read more...] about Early Communication Issued by FDA about Vytorin
Vytorin Drug Scandal to Raise Questions about FDA Oversight
Vytorin Latest Drug Scandal. The Vytorin controversy has once again raised serious questions about the way the Food & Drug Administration (FDA) approves new drugs. At issue is the agency’s policy to allow drug clinical trials to measure only “proxy markers” and not the true outcome that the medication is supposed to … [Read more...] about Vytorin Drug Scandal to Raise Questions about FDA Oversight
Big Pharma Prime for Attacks, Thanks to Defective, Ineffective Drugs
Big Pharma Defective And Ineffective Drugs. It’s not easy being a drug company these days. A recent spate of scandals over the safety or effectiveness of medications like Vytorin, Vioxx, Avandia and Ortho Evra, coupled with astronomical drug prices have made Big Pharma an easy target for politicians and consumer advocacy … [Read more...] about Big Pharma Prime for Attacks, Thanks to Defective, Ineffective Drugs
Vytorin Lawsuit Alleges Merck, Schering-Plough Knew Drug Was Ineffective
Vytorin Lawsuit Alleges Merck. The makers of Vytorin have been named as defendants in a lawsuit filed by a New York man who took the defective drug based on the belief that it offered more protection from clogged arteries, heart attacks and strokes than other, less expensive statin drugs. Sigmond Tomaszewski, who began … [Read more...] about Vytorin Lawsuit Alleges Merck, Schering-Plough Knew Drug Was Ineffective
